COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE

被引：0
|
作者：
Gossec, L. [1 ]
Goupille, P. [2 ]
Saraux, A. [3 ]
Bregman, B. [4 ]
Boccard, E. [4 ]
Dupont, D. [5 ]
Beresniak, A. [6 ]
机构：
[1] Cochin Hosp, Paris, France
[2] Univ Tours, CHRU Tours, Tours, France
[3] Hop Cavale Blanche, Brest, France
[4] Bristol Myers Squibb Co, Rueil Malmaison, France
[5] Bristol Myers Squibb Int Corp, Braine Lalleud, Belgium
[6] Descartes Univ, LIRAES, Paris, France
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66789-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A542 / A543
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness simulation model of abatacept versus anti-TNF treatment strategies in rheumatoid arthritis in France
    Saraux, Alain
    Goupille, Philippe
    Gossec, Laure
    Bregman, Bruno
    Boccard, Eric
    Dupont, Danielle
    Beresmak, Ariel
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S463 - S463
  • [2] COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA
    Alfonso-Cristancho, R.
    Aiello, E. C.
    Roa, C. N.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
  • [3] Cost-effectiveness of rituximab strategies in rheumatoid arthritis
    Seror, Raphaele
    Mariette, Xavier
    [J]. LANCET, 2017, 389 (10067): : 365 - 366
  • [4] The cost-effectiveness of abatacept versus rituximab in patients with rheumatoid arthritis: A perspective of the Canadian publicly funded health care system
    Yuan, Y.
    Maier-Moldovan, M.
    Maclean, R.
    L'Italien, G. J.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A257 - A257
  • [5] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [6] ABATACEPT OR INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN VENEZUELA? A COST-EFFECTIVENESS ANALYSIS
    Alfonso-Cristancho, R.
    Serra, N.
    Aiello, E. C.
    Roa, C. N.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A126 - A127
  • [7] A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
    Brodszky, V
    Borgstrom, F.
    Arnetorp, S.
    Pentek, M.
    Gulacsi, L.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A549 - A550
  • [8] Cost-effectiveness analysis of rituximab for rheumatoid arthritis in Taiwan
    Lou, S. F.
    Chen, D. Y.
    Cheng, T. T.
    Huang, C. M.
    Lin, H. Y.
    Su, C. C.
    Tsai, W. C.
    Tseng, J. C.
    Wei, C. C.
    Yang, L.
    Hazard, S.
    Chang, D. M.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A257 - A258
  • [9] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
  • [10] Modelling of the cost-effectiveness of rituximab for treatment of rheumatoid arthritis in Italy
    De, VS
    Giuliani, G
    Diamantopoulos, A
    Brown, B
    Kielhorn, A
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A26 - A26
12345